Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial-Reference-Cited by-同舟云学术

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial

Published:2020-10 Issue:10 Volume:7 Page:e666-e676
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Venter Willem D F,Sokhela Simiso,Simmons Bryony,Moorhouse Michelle,Fairlie Lee,Mashabane Nkuli,Serenata Celicia,Akpomiemie Godspower,Masenya Masebole,Qavi Ambar,Chandiwana Nomathemba,McCann Kaitlyn,Norris Shane,Chersich Matthew,Maartens Gary,Lalla-Edward Samanta,Vos Alinda,Clayden Polly,Abrams Elaine,Arulappan Natasha,Hill Andrew

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference30 articles.

1. The WHO public health approach to HIV treatment and care: looking back and looking ahead;Ford;Lancet Infect Dis,2018

2. Update of recommendations on first- and second-line antiretroviral regimens,2019

3. Current and future priorities for the development of optimal HIV drugs;Vitoria;Curr Opin HIV AIDS,2019

4. Are new antiretroviral treatments increasing the risks of clinical obesity?;Hill;J Virus Erad,2019

5. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines;Phillips;Lancet HIV,2020

Cited by 174 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV;HIV RES CLIN PRACT;2024

2. Weight Gain and Antiretroviral Therapy;Infectious Disease Clinics of North America;2024-09

3. Atherosclerosis and Cardiovascular Complications in People Living with HIV: A Focused Review;Infectious Disease Reports;2024-09-01

4. Metabolic Complications Associated with Use of Integrase Strand Transfer Inhibitors (InSTI) for the Treatment of HIV-1 Infection: Focus on Weight Changes, Lipids, Glucose and Bone Metabolism;Current HIV/AIDS Reports;2024-08-29

5. Deconvoluting the contribution of antiretroviral choice in weight gain;AIDS;2024-08-29